| Literature DB >> 23634174 |
Thanasekaran Jayakumar1, Cheng-Ying Hsieh, Jie-Jen Lee, Joen-Rong Sheu.
Abstract
Andrographis paniculata (Burm. F) Nees, generally known as "king of bitters," is an herbaceous plant in the family Acanthaceae. In China, India, Thailand, and Malaysia, this plant has been widely used for treating sore throat, flu, and upper respiratory tract infections. Andrographolide, a major bioactive chemical constituent of the plant, has shown anticancer potential in various investigations. Andrographolide and its derivatives have anti-inflammatory effects in experimental models asthma, stroke, and arthritis. In recent years, pharmaceutical chemists have synthesized numerous andrographolide derivatives, which exhibit essential pharmacological activities such as those that are anti-inflammatory, antibacterial, antitumor, antidiabetic, anti-HIV, antifeedant, and antiviral. However, what is noteworthy about this paper is summarizing the effects of andrographolide against cardiovascular disease, platelet activation, infertility, and NF- κ B activation. Therefore, this paper is intended to provide evidence reported in relevant literature on qualitative research to assist scientists in isolating and characterizing bioactive compounds.Entities:
Year: 2013 PMID: 23634174 PMCID: PMC3619690 DOI: 10.1155/2013/846740
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Morphology of Andrographis paniculata.
Figure 2Chemical structure of andrographolide.
Figure 3Hypothetical scheme shows the inhibitory signaling of andrographolide in platelet activation. Andrographolide can activate the endothelial nitric oxide synthase- (eNOS-) NO-cyclic GMP pathway, followed by the inhibition of both the PLCγ2-DAG-PKC and PI3 kinase/Akt cascades, and ultimately inhibits platelet aggregation [120].
Dosage and toxicity of Andrographis paniculata and its major natural product andrographolide.
| Products name | Dosage/duration/route | Experimental models | Toxic effects | References |
|---|---|---|---|---|
| Andrographolide | 10 mg/kg for 3 weeks | Human | No | [ |
| Andrographolide | 500 mg/kg bw for 7 days i.p. | Mice | No | [ |
| Andrographolide | 25–75 | Platelets | No cytotoxicity | [ |
|
| 20 mg/kg bw for 60 days, oral | Rats | No | [ |
| Andrographolide | 22–55 | Mice | Lower mortality | [ |
|
| 1 g/kg/day for 4, 6, and 8 weeks | Rats | No | [ |
| Andrographolide | 100 mg/kg, i.p. | Mice | No | [ |
| Andrographolide | 10 mg/kg, i.v. | Rats | No | [ |
i.p.: intraperitoneal; i.v.: intravenous; and bw: body weight.
Effect of andrographolide on mortality of acute pulmonary thrombosis caused by intravenous injection of ADP in experimental mice.
| Total no. | Number of | Mortality | |
|---|---|---|---|
| Solvent control (0.5 DMSO) | 6 | 0 | 0 |
| ADP (700 mg/kg) | 10 | 9 | 90 |
| ADP (700 mg/kg) + | |||
| andrographolide ( | |||
| 22 | 10 | 6 | 60* |
| 55 | 10 | 5 | 50* |
ADP: adenosine diphosphate; DMSO: dimethyl sulfoxide.
*P < 0.05 (compared with ADP control).
Experimental and clinical pharmacology of Andrographis paniculata and its major phytoconstituent andrographolide.
| Pharmacological effects | Mechanisms | References |
|---|---|---|
| (I) Experimental studies | ||
|
| ||
| ↑ CAT, SOD, and GST; | ||
| Antioxidant activity | ↓ LDH | [ |
| ↑ CAT, SOD, and GSH | [ | |
| ↓ TBARS | [ | |
|
| ||
| Anti-inflammatory effects | ↓ LPS-induced NO production | [ |
|
| ||
| Anticancer effects | ↑ Cell differentiation | [ |
| ↓ Proliferation of cancer cells | [ | |
| ↑ IL-2 and IFN-c | [ | |
| ↓ Tumour growth | ||
| ↓ Cell proliferation, migration, and cell cycle arrest at G2/M phase | [ | |
| ↓ E-selectin expression | [ | |
| ↓ Janus tyrosine kinases-signal transducers and activators of transcription, phosphatidylinositol 3-kinase and NF- | ||
| ↑ Tumor suppressor proteins p53 and p21 | [ | |
|
| ||
| Immunomodulatory effect | ↑ Antibody production | [ |
| ↓ Delayed-type hypersensitivity response | ||
| ↑ Proliferation of human peripheral blood lymphocytes | ||
| Key cytokines and the expression | [ | |
|
| ||
| ↓ ALT activity | [ | |
| Hepatoprotective effects | ↓ Concanavalin A-induced liver injury and hepatocyte apoptosis | [ |
| ↓ GOT, GPT, ACP, and ALP levels | [ | |
|
| ||
| Antimicrobial effects | Acted against herpes simplex virus 1 (HSV-1) | [ |
| Acted against nine bacterial strains such as | ||
|
| ||
|
| [ | |
|
| ||
|
| ||
|
| ||
| ↓ Herpes simplex virus (HSV) | [ | |
| Antiviral effects | Human immunodeficiency virus (HIV) | [ |
| Flaviviruses and pestiviruses | [ | |
| Dengue virus (DENV1) | [ | |
|
| ||
| Larvicidal and ovicidal effects | Affected the larval growth of | [ |
| Ovicidal activity against various age groups of | [ | |
| Larvicidal and ovicidal activities against | [ | |
|
| ||
| Renoprotective effects | ↓ Gentamicin-induced increase in serum creatinine, | [ |
| serum urea, and blood urea nitrogen levels | ||
|
| ||
| ↓ Spermatogenesis | [ | |
| Antifertility effects | ↓ Degenerative changes in the seminiferous tubules, regression of Leydig cells, and regressive and/or degenerative changes in the epididymis, seminal vesicle, | [ |
| ↓ ventral prostate, and coagulating glands | [ | |
|
| ||
| Antihyperglycemic activity | ↓ TG | [ |
| ↓ Blood glucose level | [ | |
|
| ||
| Hypolipidemic effects | ↓ TC, TG, HDL-TC, and LDL-TC | [ |
| ↓ Blood glucose, triglyceride, and LDL | [ | |
|
| ||
| Cardiovascular effects | Limiting blood flow to the brain, heart, and bodies of other organs | [ |
| Protect rat cardiomyocytes against | ||
| hypoxia injury by increasing GSH | [ | |
| and antioxidant enzyme | ||
| ↓ Coronary perfusion pressure | [ | |
|
| ||
| ↓ Platelet-activating factor (PAF) | [ | |
| Inhibitory effects on platelet aggregation | ↑ eNOS-NO/cyclic GMP pathway | [ |
| ↓ PLC | ||
|
| ||
| Inhibitory effects on NF-kappa B activation | ↓ NF- | [ |
| ↓ NF- | [ | |
|
| ||
| (II) Clinical studies | ||
|
| ||
| Anti-HIV effect | ↑ CD4+ lymphocyte count | [ |
| ↓ gp120-mediated cell fusion of HL2/3 cells with TZM-bl cells | [ | |
|
| ||
| Effects on upper respiratory tract infections | ↓ Relieving the symptoms of fever and sore throat | [ |
| Tiredness, sleeplessness, sore throat, and nasal secretion | [ | |
CAT: catalase; SOD: superoxide dismutase; GST: glutathione-S-transferase; LDH: lactate dehydrogenase; TBARS: thiobarbituric-acid-reactive substances; LPS: lipopolysaccharides; NO: nitric oxide; IL-2: interleukin-2; IFN-c: interferon-c; GOT: glutamate oxaloacetate transaminase; GPT: glutamate pyruvate transaminase; ALP: alkaline phosphatase; ACP: acid phosphatase; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B “e” antigen; ALT: alanine aminotransferase; TC: total cholesterol; TG: triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein; GHS: reduced glutathione; PLC-γ2: phospholipase C; PKC: protein kinase C; MAPK: mitogen-activated protein kinase; cGMP: cyclic guanosine monophosphate; eNOS: endothelial nitric oxide synthase; HSP: heat shock protein; MMP: matrix metalloproteinases.